Stock SANA SANA BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sana Biotechnology, Inc.

Equities

SANA

US7995661045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
7.61 USD -1.55% Intraday chart for Sana Biotechnology, Inc. -15.07% +86.52%
Apr. 09 Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024. CI
Apr. 09 Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
AQ
Certain Restricted Stock Units of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
CI
Certain Stock Options of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
CI
Certain Common Stock of Sana Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 9-APR-2024.
CI
JMP Securities Adjusts Sana Biotechnology Price Target to $15 From $8, Maintains Market Outperform Rating
MT
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows
MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline
MT
Sana: Q4 Earnings Snapshot
AQ
Sana Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sana Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GL
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
GL
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer
MT
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
GL
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
AQ
Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP
CI
Breaking Ground in BioPharma: Spotlight Companies DYAI, INBS, SANA, IOVA, BLUE
AQ
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing
MT
Sana Biotechnology Insider Bought Shares Worth $9,999,996, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SANA Stock
  4. News Sana Biotechnology, Inc.